This article was originally published in The Gray Sheet
Executive SummaryVagus nerve stimulation system developer raises $45 mil. in a private placement of 2.5 mil. common shares at $18 each. Proceeds will be used to fund ongoing and future clinical trials in depression, obesity and anxiety, the firm reports Feb. 14. Company's 21-center, 210-patient U.S. pivotal study for depression has enrolled 136 patients to date. Pilot studies in obesity and Alzheimer's are underway, and the firm also has an approved IDE for a 30-patient, four-center pilot study set to begin in fiscal 2001 of left cervical vagus nerve stimulation for three major anxiety disorders. US Bancorp Piper Jaffray acted as placement agent for the financing
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.